May 6 (Reuters) - Carmat SA ALCAR.PA :
* CARMAT CONTINUES TO BUILD ON ITS MOMENTUM IN THE EFICAS
STUDY
AND REITERATES CONFIDENCE IN ITS 2024 OUTLOOK
* CONFIRMATION OF SHORT-TERM FINANCIAL SUPPORT FROM SEVERAL
KEY
SHAREHOLDERS
* EFICAS STUDY REACHES MILESTONE OF 20 IMPLANTS
* INTERIM STUDY RESULTS ABOVE EXPECTATIONS
* CONFIRMS ITS TARGET OF COMPLETING EFICAS STUDY, WITH A
TOTAL OF
52 AESON IMPLANTS, IN FIRST HALF OF 2025
* GIVEN ITS CASH POSITION AND BUSINESS PLAN, COMPANY'S
FINANCIAL
HORIZON CURRENTLY EXTENDS TO END OF MAY 2024
* ESTIMATES ITS 12-MONTH FINANCING REQUIREMENT AT AROUND EUR
45
MILLION
Source text for Eikon: ID:nBw215xc0a
Further company coverage: ALCAR.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))